000291113 001__ 291113
000291113 005__ 20250818141157.0
000291113 0247_ $$2doi$$a10.1016/j.jinf.2024.106206
000291113 0247_ $$2pmid$$apmid:38897239
000291113 0247_ $$2ISSN$$a0163-4453
000291113 0247_ $$2ISSN$$a1532-2742
000291113 0247_ $$2altmetric$$aaltmetric:164651111
000291113 037__ $$aDKFZ-2024-01316
000291113 041__ $$aEnglish
000291113 082__ $$a610
000291113 1001_ $$aMikolajczyk, Rafael$$b0
000291113 245__ $$aLikelihood of Post-COVID Condition in people with hybrid immunity; data from the German National Cohort (NAKO).
000291113 260__ $$aAmsterdam [u.a.]$$bElsevier$$c2024
000291113 3367_ $$2DRIVER$$aarticle
000291113 3367_ $$2DataCite$$aOutput Types/Journal article
000291113 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1721285718_2267
000291113 3367_ $$2BibTeX$$aARTICLE
000291113 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000291113 3367_ $$00$$2EndNote$$aJournal Article
000291113 500__ $$a2024 Jun 17;89(2):106206
000291113 520__ $$aThe risk of Post-COVID-19 condition (PCC) under hybrid immunity remains unclear.Using data from the German National Cohort (NAKO Gesundheitsstudie), we investigated risk factors for self-reported post-infection symptoms (any PCC is defined as having at least one symptom, and high symptom burden PCC as having nine or more symptoms).Sixty percent of 109,707 participants reported at least one previous SARS-CoV-2 infection; 35% reported having had any symptoms 4-12 months after infection; among them 23% reported nine or more symptoms. Individuals, who did not develop PCC after their first infection, had a strongly reduced risk for PCC after their second infection (50%) and a temporary risk reduction, which waned over nine months after the preceding infection. The risk of developing PCC strongly depended on the virus variant. Within variants, there was no effect of the number of preceding vaccinations, apart from a strong protection by the fourth vaccination compared to three vaccinations for the Omicron variant (odds ratio=0.52; 95% confidence interval 0.45-0.61).Previous infections without PCC and a fourth vaccination were associated with a lower risk of PCC after a new infection, indicating diminished risk under hybrid immunity. The two components of risk reduction after a preceding infection suggest different immunological mechanisms.
000291113 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000291113 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000291113 650_7 $$2Other$$aHybrid Immunity
000291113 650_7 $$2Other$$aPost-COVID-19 condition
000291113 650_7 $$2Other$$aReinfection
000291113 650_7 $$2Other$$aSARS-CoV-2
000291113 650_7 $$2Other$$aVaccination
000291113 7001_ $$aDiexer, Sophie$$b1
000291113 7001_ $$aKlee, Bianca$$b2
000291113 7001_ $$aPfrommer, Laura$$b3
000291113 7001_ $$aPurschke, Oliver$$b4
000291113 7001_ $$aFricke, Julia$$b5
000291113 7001_ $$aAhnert, Peter$$b6
000291113 7001_ $$aGabrysch, Sabine$$b7
000291113 7001_ $$aGottschick, Cornelia$$b8
000291113 7001_ $$aBohn, Barbara$$b9
000291113 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b10$$udkfz
000291113 7001_ $$aBuck, Christoph$$b11
000291113 7001_ $$aCastell, Stefanie$$b12
000291113 7001_ $$aGastell, Sylvia$$b13
000291113 7001_ $$0P:(DE-He78)e0ac0d57cdb66d87f2d95ae5f6178c1b$$aGreiser, Karin Halina$$b14$$udkfz
000291113 7001_ $$aHarth, Volker$$b15
000291113 7001_ $$aHeise, Jana-Kristin$$b16
000291113 7001_ $$aHolleczek, Bernd$$b17
000291113 7001_ $$0P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a$$aKaaks, Rudolf$$b18$$udkfz
000291113 7001_ $$aKeil, Thomas$$b19
000291113 7001_ $$aKrist, Lilian$$b20
000291113 7001_ $$aLeitzmann, Michael$$b21
000291113 7001_ $$aLieb, Wolfgang$$b22
000291113 7001_ $$aMeinke-Franze, Claudia$$b23
000291113 7001_ $$aMichels, Karin B$$b24
000291113 7001_ $$aVelásquez, Ilais Moreno$$b25
000291113 7001_ $$aObi, Nadia$$b26
000291113 7001_ $$aPanreck, Leo$$b27
000291113 7001_ $$aPeters, Annette$$b28
000291113 7001_ $$aPischon, Tobias$$b29
000291113 7001_ $$aSchikowski, Tamara$$b30
000291113 7001_ $$aSchmidt, Börge$$b31
000291113 7001_ $$aStandl, Marie$$b32
000291113 7001_ $$aStang, Andreas$$b33
000291113 7001_ $$aVölzke, Henry$$b34
000291113 7001_ $$aWeber, Andrea$$b35
000291113 7001_ $$aZeeb, Hajo$$b36
000291113 7001_ $$aKarch, André$$b37
000291113 773__ $$0PERI:(DE-600)2012883-6$$a10.1016/j.jinf.2024.106206$$gp. 106206 -$$n2$$p106206$$tJournal of infection$$v89$$x0163-4453$$y2024
000291113 8564_ $$uhttps://inrepo02.dkfz.de/record/291113/files/1-s2.0-S0163445324001403-main.pdf
000291113 8564_ $$uhttps://inrepo02.dkfz.de/record/291113/files/1-s2.0-S0163445324001403-main.pdf?subformat=pdfa$$xpdfa
000291113 909CO $$ooai:inrepo02.dkfz.de:291113$$pVDB
000291113 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000291113 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)e0ac0d57cdb66d87f2d95ae5f6178c1b$$aDeutsches Krebsforschungszentrum$$b14$$kDKFZ
000291113 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a$$aDeutsches Krebsforschungszentrum$$b18$$kDKFZ
000291113 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000291113 9141_ $$y2024
000291113 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2023-08-26$$wger
000291113 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-26
000291113 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-26
000291113 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-08-26
000291113 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-26
000291113 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-08-26
000291113 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-08-26
000291113 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ INFECTION : 2022$$d2023-08-26
000291113 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-26
000291113 915__ $$0StatID:(DE-HGF)9925$$2StatID$$aIF >= 25$$bJ INFECTION : 2022$$d2023-08-26
000291113 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000291113 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x1
000291113 980__ $$ajournal
000291113 980__ $$aVDB
000291113 980__ $$aI:(DE-He78)C070-20160331
000291113 980__ $$aI:(DE-He78)C020-20160331
000291113 980__ $$aUNRESTRICTED